KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Revenue (2016 - 2025)

Historic Revenue for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $192.1 million.

  • Supernus Pharmaceuticals' Revenue rose 934.26% to $192.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $681.5 million, marking a year-over-year increase of 453.5%. This contributed to the annual value of $661.8 million for FY2024, which is 893.73% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Revenue stood at $192.1 million for Q3 2025, which was up 934.26% from $165.5 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Revenue high stood at $192.1 million for Q3 2025, and its period low was $130.9 million during Q1 2021.
  • In the last 5 years, Supernus Pharmaceuticals' Revenue had a median value of $159.0 million in 2021 and averaged $159.1 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Revenue soared by 3785.8% in 2021, and later tumbled by 2028.1% in 2023.
  • Supernus Pharmaceuticals' Revenue (Quarter) stood at $159.0 million in 2021, then rose by 5.2% to $167.3 million in 2022, then dropped by 1.8% to $164.3 million in 2023, then rose by 5.99% to $174.2 million in 2024, then increased by 10.3% to $192.1 million in 2025.
  • Its last three reported values are $192.1 million in Q3 2025, $165.5 million for Q2 2025, and $149.8 million during Q1 2025.